Business context and reporting period
Entity discrepancy: The supplied filing is Trxade Group, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020—not a filing under the metadata name Scienture Holdings, Inc. Trxade operates a pharmaceutical marketplace and also owns pharmacy, wholesaler, delivery-software and telehealth businesses.
Financial performance and position
| Metric | Q1 2020 | Q1 2019 / prior date |
|---|---|---|
| Revenue | $2.203 million | $1.513 million; up 45.7% |
| Gross profit / margin | $1.640 million / 74.4% | $1.147 million / 75.8% |
| Operating income / margin | $188,227 / 8.5% | $171,759 / 11.4% |
| Net income | $180,303; basic EPS $0.03, diluted EPS $0.02 | $125,229; basic and diluted EPS $0.02 |
| Operating cash flow | $(410,806) | $(125,794) |
| Cash / working capital | $7.701 million / $8.844 million | $2.872 million / $3.282 million at Dec. 31, 2019 |
| Total liabilities | $1.837 million | $1.431 million at Dec. 31, 2019 |
Cost of sales was $563,184, up 53.9%; general and administrative expense was $1.452 million, up 48.9%, including $141,086 in warrant and option expense. Related-party notes payable were $225,000, bearing 10% interest and maturing in October 2021. Lease liabilities totaled $751,837, including $90,759 current. The company reported no off-balance-sheet arrangements.
Material changes and financing
- Platform revenue rose with increased sales of generic products and customer additions. Integra Pharma revenue increased to $245,016 from $26,288; Community Specialty Pharmacy revenue was $432,929 versus $442,423.
- In February, the company sold 922,219 shares at $6.50 per share. It received approximately $5.99 million gross and approximately $5.17 million net of $820,586 in offering costs. Cash increased by $4.83 million during the quarter, principally from the offering.
- Inventory and inventory-purchase deposits rose to $368,401 and $580,800, respectively. Management attributed higher operating cash use chiefly to the deposits. In April, $295,800 of deposits was returned because suppliers lacked the specified products.
- The company terminated its SyncHealth joint venture effective January 31, 2020 and assigned its 30% interest back to the other party; no equity-method loss was recorded in Q1 2020, compared with a $28,972 loss in Q1 2019.
- A 1-for-6 reverse stock split became effective in February; share and per-share data were retroactively adjusted. Shares outstanding were 7,484,370 at quarter-end.
Outlook, risks and other matters
- Management estimated approximately $5 million of general and administrative and working-capital requirements for the next 12 months, and said available cash was sufficient for the foreseeable future. It gave no specific revenue or earnings guidance; future acquisitions or growth may require additional financing, which could be dilutive or unavailable on favorable terms.
- COVID-19-related supply interruptions and remote work were identified as potential material pressures on operations, pharmaceutical availability, wholesalers, technology outsourcing and Q2/full-year 2020 results. The company delayed anticipated Bonum Health Hub installations until 2021 at the earliest.
- A pending lawsuit seeks $425,000 in compensatory and $1.275 million in punitive damages. The company denies the allegations; a hearing on its motion to dismiss was postponed. The company said it could not estimate a probable or reasonably possible loss.
- Management concluded disclosure controls were ineffective and cited material weaknesses in written accounting/reporting procedures and period-end reporting controls. It said it was adding expertise and developing policies and checklists.
- Subsequent events included a $10,000 SBA Economic Injury Disaster Loan that the company was in the process of returning, and material equity compensation and executive compensation actions approved in April.
Most important facts to verify
- Confirm the issuer identity: the filing names Trxade Group, Inc., despite the request metadata naming Scienture Holdings, Inc.
- Assess whether inventory deposits are recoverable and whether supplier shortages affect sales, margins or working capital.
- Review dilution from the February offering, outstanding options and warrants, and April equity awards.
- Monitor COVID-19 effects, Bonum Health deployment timing, and management’s cash-use assumptions against the stated $5 million estimate.
- Track the lawsuit and the remediation of disclosed financial-reporting control weaknesses.